Professional Practice Fellow, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
National Poisons Centre, University of Otago, Dunedin, New Zealand.
Clin Toxicol (Phila). 2023 Jun;61(6):415-428. doi: 10.1080/15563650.2023.2212125. Epub 2023 Jun 2.
Ketamine is a pharmaceutical drug possessing both analgesic and anaesthetic properties. As an anaesthetic, it induces anaesthesia by producing analgesia with a state of altered consciousness while maintaining airway tone, respiratory drive, and hemodynamic stability. At lower doses, it has psychoactive properties and has gained popularity as a recreational drug.
To review the epidemiology, mechanisms of toxicity, pharmacokinetics, clinical features, diagnosis and management of ketamine toxicity.
Both OVID MEDLINE (January 1950-April 2023) and Web of Science (1900-April 2023) databases were searched using the term "ketamine" in combination with the keywords "pharmacokinetics", "kinetics", "poisoning", "poison", "toxicity", "ingestion", "adverse effects", "overdose", and "intoxication". Furthermore, bibliographies of identified articles were screened for additional relevant studies. These searches produced 5,268 non-duplicate citations; 185 articles (case reports, case series, pharmacokinetic studies, animal studies pertinent to pharmacology, and reviews) were considered relevant. Those excluded were other animal investigations, therapeutic human clinical investigations, commentaries, editorials, cases with no clinical relevance and post-mortem investigations.
Following its introduction into medical practice in the early 1970s, ketamine has become a popular recreational drug. Its use has become associated with the dance culture, electronic and dubstep dance events.
Ketamine acts primarily as a non-competitive antagonist on the glutamate N-methyl-D-aspartate receptor, causing the loss of responsiveness that is associated with clinical ketamine dissociative anaesthesia.
Absorption of ketamine is rapid though the rate of uptake and bioavailability is determined by the route of exposure. Ketamine is metabolized extensively in the liver. Initially, both isomers are metabolized to their major active metabolite, norketamine, by CYP2B6, CYP3A4 and CYP2C9 isoforms. The hydroxylation of the cyclohexan-1-one ring of norketamine to the three positional isomers of hydroxynorketamine occurs by CYP2B6 and CYP2A6. The dehydronorketamine metabolite occurs either by direct dehydrogenation from norketamine via CYP2B6 metabolism or non-enzymatic dehydration of hydroxynorketamine. Norketamine, the dehydronorketamine isomers, and hydroxynorketamine have pharmacological activity. The elimination of ketamine is primarily by the kidneys, though unchanged ketamine accounts for only a small percentage in the urine. The half-life of ketamine in humans is between 1.5 and 5 h.
Acute adverse effects following recreational use are diverse and can include impaired consciousness, dizziness, irrational behaviour, hallucinations, abdominal pain and vomiting. Chronic use can result in impaired verbal information processing, cystitis and cholangiopathy.
The diagnosis of acute ketamine intoxication is typically made on the basis of the patient's history, clinical features, such as vomiting, sialorrhea, or laryngospasm, along with neuropsychiatric features. Chronic effects of ketamine toxicity can result in cholangiopathy and cystitis, which can be confirmed by endoscopic retrograde cholangiopancreatography and cystoscopy, respectively.
Treatment of acute clinical toxicity is predominantly supportive with empiric management of specific adverse effects. Benzodiazepines are recommended as initial treatment to reduce agitation, excess neuromuscular activity and blood pressure. Management of cystitis is multidisciplinary and multi-tiered, following a stepwise approach of pharmacotherapy and surgery. Management of cholangiopathy may require pain management and, where necessary, biliary stenting to alleviate obstructions. Chronic effects of ketamine toxicity are typically reversible, with management focusing on abstinence.
Ketamine is a dissociative drug employed predominantly in emergency medicine; it has also become popular as a recreational drug. Its recreational use can result in acute neuropsychiatric effects, whereas chronic use can result in cystitis and cholangiopathy.
氯胺酮是一种具有镇痛和麻醉特性的药物。作为一种麻醉剂,它通过产生镇痛作用诱导麻醉,同时保持气道张力、呼吸驱动和血流动力学稳定,改变意识状态。在较低剂量下,它具有精神活性,并已作为娱乐性药物流行起来。
综述氯胺酮毒性的流行病学、毒性机制、药代动力学、临床特征、诊断和管理。
同时在 OVID MEDLINE(1950 年 1 月至 2023 年 4 月)和 Web of Science(1900 年至 2023 年 4 月)数据库中使用术语“氯胺酮”与“药代动力学”、“动力学”、“中毒”、“中毒”、“毒性”、“摄入”、“不良反应”、“过量”和“中毒”的关键词进行搜索。此外,还筛选了已确定文章的参考文献,以寻找其他相关研究。这些搜索产生了 5268 条非重复引文;185 篇文章(病例报告、病例系列、药代动力学研究、与药理学相关的动物研究和综述)被认为是相关的。那些被排除的是其他动物研究、治疗性人体临床研究、评论、社论、没有临床相关性的病例和死后调查。
氯胺酮在 20 世纪 70 年代初引入医学实践后,已成为一种流行的娱乐性药物。它的使用与舞蹈文化、电子和 dubstep 舞蹈活动有关。
氯胺酮主要作为谷氨酸 N-甲基-D-天冬氨酸受体的非竞争性拮抗剂,导致与临床氯胺酮分离性麻醉相关的反应迟钝。
氯胺酮的吸收很快,但吸收速度和生物利用度取决于暴露途径。氯胺酮在肝脏中被广泛代谢。最初,两种对映体都被 CYP2B6、CYP3A4 和 CYP2C9 同工酶代谢为其主要活性代谢物去甲氯胺酮。去甲氯胺酮的环己烷-1-酮环的羟化作用发生在 CYP2B6 和 CYP2A6 中。羟基去甲氯胺酮的三种位置异构体通过 CYP2B6 和 CYP2A6 发生。脱水去甲氯胺酮代谢物要么通过 CYP2B6 代谢直接从去甲氯胺酮脱氢,要么通过非酶促脱水羟去甲氯胺酮发生。去甲氯胺酮、脱水去甲氯胺酮异构体和羟基去甲氯胺酮都具有药理学活性。氯胺酮的消除主要通过肾脏进行,尽管尿液中只有一小部分未改变的氯胺酮。人类氯胺酮的半衰期在 1.5 至 5 小时之间。
娱乐性使用后急性不良反应多种多样,包括意识障碍、头晕、不合理行为、幻觉、腹痛和呕吐。慢性使用可导致言语信息处理受损、膀胱炎和胆管病。
急性氯胺酮中毒的诊断通常基于患者的病史、临床特征,如呕吐、流涎或喉痉挛,以及神经精神特征。氯胺酮毒性的慢性影响可导致胆管病和膀胱炎,可通过内镜逆行胰胆管造影和膀胱镜检查分别确认。
急性临床毒性的治疗主要是支持性的,对特定不良反应进行经验性治疗。苯二氮䓬类药物被推荐作为初始治疗药物,以减少激越、过度神经肌肉活动和血压。膀胱炎的管理是多学科和多层次的,遵循逐步的药物治疗和手术方法。胆管病的管理可能需要疼痛管理,必要时需要胆道支架以缓解梗阻。氯胺酮毒性的慢性影响通常是可逆的,管理重点是戒除。
氯胺酮是一种主要用于急诊医学的分离药物;它也已作为娱乐性药物流行起来。它的娱乐性使用会导致急性神经精神效应,而慢性使用会导致膀胱炎和胆管病。